To date, the majority of the vaccines tested clinically are live, attenuated vaccines. The use of non-replicating vaccine candidates is also being explored. For example, Ivy *et al*. (U.S. Patent 6,432,411) disclose a tetravalent subunit vaccine comprising DEN1-4 80% E (the peptide region of DEN1-4 corresponding to amino acids 1-395 of the DENV-2 envelope polypeptide) proteins. Ivy et al, *supra*, also report compositions comprising DENV 1-4 80% E and ISCOMATRIX® adjuvant. Coller *et al*. (WO 2012/154202) disclose tetravalent formulations comprising DEN1-4 80% E of DEN 1-4. Inactivated viruses may also be used as potential vaccine candidates or as components of an effective vaccine (Putnak et al. *Vaccine* 23: 4442–4452 (2005), US 6190859, US 6254873 and Sterner *et al*. WO 2007/002470). Compositions comprising a live attenuated dengue virus vaccine and a non-replicating dengue vaccine are disclosed in International Patent Application No. PCT/US14/042625 (WO2014/204892).

Whole viruses are one of the commonly used antigens in several vaccine products due to their ability to generate humoral and cellular immune responses. Vaccine products containing whole viruses are challenging to stabilize as these are sensitive to heat, freeze/thaw and other processing stresses leading to significant potency losses. These products are typically stored frozen (below -20°C) or as dried powder. Frozen products are not easy to store and distribute as they need a stringent cold-chain requirement to prevent potency loss. Drying of whole viruses, especially enveloped viruses, often leads to significant loss of potency due to the freezing and drying stresses encountered during the drying process. Therefore, there is a need in the art to generate stable formulations of Dengue virus.

SUMMARY

The current disclosure provides stable formulations of live attenuated dengue vaccine. The addition of a cellulose derivative and a sugar alcohol or glycol improved stability and/or yield after drying. Alternatively, the addition of sugar of at least 150 mg/ml improved stability and/or yield after microwave drying.

The disclosure provides a formulation comprising a live attenuated dengue vaccine comprising at least one live attenuated dengue virus (LAV) or at least one live attenuated chimeric flavivirus (LACV), a buffer at pH about 6.5 to 8.5, a sugar, a glycol or sugar alcohol, and a cellulose derivative selected from the group consisting of carboxymethyl cellulose, hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC), 2-hydroxyethyl cellulose (2-HEC), crosscarmellose, and methyl cellulose, or a pharmaceutically acceptable salt thereof; optionally an alkali or alkaline salt, and optionally an amino acid selected from the group consisting of Ala, Asp, His, Leu, Lys, Gln, Pro or Glu, or a combination thereof.

In one aspect, the disclosure provides a formulation that comprises the following components: a) a live attenuated tetravalent dengue vaccine comprising i) 100-10,000,000 pfu/ml rDEN1Δ30 virus, ii) 100-10,000,000 pfu/ml rDEN2/4Δ30 virus, iii) 100-10,000,000 pfu/ml

rDEN3Δ30/31 virus, and iv) 100-10,000,000 pfu/ml rDEN4Δ30 virus, b) about 11 mM potassium phosphate buffer, c) about 90 mg/ml sucrose, d) about 5 mg/ml propylene glycol, e) about 5 mg/ml sodium carboxymethylcellulose, f) about 50 mM NaCl, and g) about 25 mM Leu, wherein the formulation is at a pH of 7.0 to 8.0.

In another aspect, the disclosure provides a formulation hat comprises the following components: a) a live attenuated tetravalent dengue vaccine comprising i) 100-10,000,000 pfu/ml rDEN1Δ30 virus, ii) 100-10,000,000 pfu/ml rDEN2/4Δ30 virus, iii) 100-10,000,000 pfu/ml rDEN3Δ30/31 virus, and iv) 100-10,000,000 pfu/ml rDEN4Δ30 virus, b) 11 mM potassium phosphate buffer, c) 90 mg/ml sucrose, d) 5 mg/ml propylene glycol, e) 5 mg/ml sodium carboxymethylcellulose, f) 50 mM NaCl, and g) 25 mM Leu, wherein the formulation is at a pH of 7.0 to 8.0.

In one example, the buffer is selected from the group consisting of succinate, histidine, phosphate, TRIS, Bis-Tris, MES, MOPS, HEPES, acetate and citrate, or a combination

K12. In an example, the formulation further comprises a surfactant selected from poloxamer 188 and poloxamer 407 at about 0.0001 to 5% w/v.

In one example, the formulation further comprises an aluminum adjuvant. The above formulations can be frozen or lyophilized, or reconstituted in solution. In one example, the reconstitution is performed with about 0.5-1.0 ml saline solution, water or Bacteriostatic Water for Injection (BWFI) and optionally a diluent comprising an aluminum adjuvant. In another example, the formulation is the aqueous solution prior to lyophilization or microwave vacuum drying.

In one example, the live attenuated dengue vaccine comprises tetravalent live attenuated dengue virus or live attenuated chimeric flavivirus. In another example, the LAV or the LACV comprise a viral genome that contains a deletion of about 30 nucleotides corresponding to the TL-2 stem-loop structure of the 3' untranslated (UTR) region; which reduces the replicative capacity of the virus. In a further example, the live attenuated dengue virus is an LAV that comprise a viral genome that contains a deletion of about 30 nucleotides corresponding to the TL-2 stem-loop structure of the 3' untranslated (UTR) region, and is immunogenic against dengue serotype 3, wherein the viral genome of the LAV further contains a deletion of nucleotides upstream from the Δ30 deletion corresponding to the TL-3 structure of the 3'UTR.

In preferred examples of the disclosure, the live attenuated dengue vaccine is a live attenuated tetravalent vaccine comprising a DEN1Δ30 virus, a DEN2/4Δ30 virus (a DEN2 Δ30LACV on a DEN4 backbone), a DEN3Δ30 virus and a DEN4Δ30 virus. In another preferred example, the live attenuated dengue virus is an LAV comprising rDEN1Δ30-1545, rDEN2/4Δ30 (ME)-1495,7163, rDEN3Δ30/31-7164, and rDEN4Δ30-7132,7163,8308.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1: Effect of Sodium CMC, PG, amino acids on DENV4 lyophilization yield for DEN4 formulations.

FIG. 2: Effect of Sodium CMC, PG, amino acids on DENV4 stability for DEN4 formulations. Formulation 26 (*) was not tested due to cake collapse after storage at 25°C.

FIG. 3: Effect of sugar alcohol on DENV4 lyophilization yield for DEN4 formulations.

FIG. 4: Effect of sugar alcohol on DENV4 stability for DEN4 formulations.

FIG. 5: Effect of pH on DENV4 lyophilization yield for DEN4 formulations.

FIG. 6: Effect of pH on DENV4 stability for DEN4 formulations.

FIG. 7: Effect of buffer on DENV4 lyophilization yield for DEN4 formulations.

FIG. 8: Effect of buffer on DENV4 stability for DEN4 formulations.

FIG. 9: Effect of NaCl concentration on DENV4 lyophilization yield. for DEN4 formulations.

FIG. 10: Effect of NaCl concentration on DENV4 stability for DEN4 formulations.

FIG. 11: Effect of propylene glycol and glyercol on lyophilization yields of Dengue serotypes.

WHAT IS CLAIMED IS:

1. A formulation that comprises the following components:

a) a live attenuated tetravalent dengue vaccine comprising i) 100-10,000,000 pfu/ml rDEN1Δ30 virus, ii) 100-10,000,000 pfu/ml rDEN2/4Δ30 virus, iii) 100-10,000,000 pfu/ml rDEN3Δ30/31 virus, and iv) 100-10,000,000 pfu/ml rDEN4Δ30 virus,

b) about 11 mM potassium phosphate buffer,

c) about 90 mg/ml sucrose,

d) about 5 mg/ml propylene glycol,

e) about 5 mg/ml sodium carboxymethylcellulose,

f) about 50 mM NaCl, and

g) about 25 mM Leu,

wherein the formulation is at a pH of 7.0 to 8.0.

2. The formulation of claim 1 wherein the formulation is at a pH of about 7.5.

3. The formulation of claim 1 wherein the vaccine comprises i) 200-200,000 pfu/ml rDEN1Δ30 virus, ii) 200-200,000 pfu/ml rDEN2/4Δ30 virus, iii) 200-200,000 pfu/ml rDEN3Δ30/31 virus, and iv) 200-200,000 pfu/ml rDEN4Δ30 virus.

4. The formulation of claim 1 wherein the rDEN1Δ30 is rDEN1Δ30-1545; the rDEN2/4Δ30 is rDEN2/4Δ30 (ME)-1495,7163; the rDEN3Δ30/31 is rDEN3Δ30/31-7164; and rDEN4Δ30 is rDEN4Δ30-7132,7163,8308.

5. A formulation hat comprises the following components:

a) a live attenuated tetravalent dengue vaccine comprising i) 100-10,000,000 pfu/ml rDEN1Δ30 virus, ii) 100-10,000,000 pfu/ml rDEN2/4Δ30 virus, iii) 100-10,000,000 pfu/ml rDEN3Δ30/31 virus, and iv) 100-10,000,000 pfu/ml rDEN4Δ30 virus,

b) 11 mM potassium phosphate buffer,

c) 90 mg/ml sucrose,

d) 5 mg/ml propylene glycol,

e) 5 mg/ml sodium carboxymethylcellulose,

f) 50 mM NaCl, and

g) 25 mM Leu,

wherein the formulation is at a pH of 7.0 to 8.0.

6. The formulation of claim 5 wherein the formulation is at a pH of 7.5.

7. The formulation of claim 5 wherein the vaccine comprises i) 200-200,000 pfu/ml rDEN1Δ30 virus, ii) 200-200,000 pfu/ml rDEN2/4Δ30 virus, iii) 200-200,000 pfu/ml rDEN3Δ30/31 virus, and iv) 200-200,000 pfu/ml rDEN4Δ30 virus.

8. The formulation of claim 5 wherein the rDEN1Δ30 is rDEN1Δ30-1545; the rDEN2/4Δ30 is rDEN2/4Δ30 (ME)-1495,7163; the rDEN3Δ30/31 is rDEN3Δ30/31-7164; and rDEN4Δ30 is rDEN4Δ30-7132,7163,8308.

5